

**INFORMATION DISCLOSURE STATEMENT**  
(37 CFR 1.96, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET 22660-0025 D1 C1	APPLICATION NO. not yet assigned
APPLICANT(S) McMillen et al	
FILING DATE December 19, 2001	GROUP not yet assigned

**US PATENT DOCUMENTS**

EXR INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (if appropriate)
AC	*A1	5,219,727	6/1993	Wang et al	435/6	
	*A2	5,476,774	12/1995	Wang et al	435/91.2	
	*A3	5,710,029	1/1998	Ryder et al	435/911	
	*A4	5,747,248	5/1998	Pennetier et al	435/6	
	*A5	5,766,889	5/1998	Alwood	435/91.2	
	*A6	5,824,255	1/1998	van Gerven et al.	435/91.2.1	
	*A7	5,837,501	1/1998	Baumert et al.	435/91.2	
	*A8	5,863,736	1/1998	Hasland	435/6	
	*A9	6,066,458	5/2000	Hasland	435/6	
	*A10	6,080,574	8/2000	Brendt	435/288.7	
	*A11	6,174,870	1/2001	Wither et al	435/6	
	*A12	6,232,078	5/2001	Wither et al	435/6	
	*A13	6,294,338	8/2001	Nunomura	435/6	
	*A14	6,303,305	10/2001	Wither et al	435/6	

**FOREIGN PATENT DOCUMENTS**

EXR INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	*B1	EP0640828 A1	6/1994	EP	
	*B2	WO 87/48707	6/1988	WO	
	*B3	EP0497764	7/1989	EP	

**OTHER DOCUMENTS**

EXR INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Paragraph, Pages, etc.)
AC	*C1	LightCycler Operator's Manual Version 3.0, May 1999, Roche Pharmaceuticals
EXAMINER'S SIGNATURE		DATE CONSIDERED
H. H. Chakrabarti		7/10/02

EXAMINER: Initial if reference is considered, checked if not shown in communication with MPEP 802. Link through classif if not in communication and not considered. Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 121. 37 CFR 1.96(b).